CCL22 and neoplasm: As shown in breast cancer research studies, these cells in the tumor niche express CCR8 (receptor for CCL1/I-309) and CCR4 (receptor for CCL17/thymus and activation regulated chemokine (TARC) and CCL22/macrophage derived chemokine (MDC)) [119,120].